Fig. 10: Therapeutic effects of CNP-53 in SuHx rodent models and its additive benefits with established therapies. | Nature Communications

Fig. 10: Therapeutic effects of CNP-53 in SuHx rodent models and its additive benefits with established therapies.

From: Endothelial C-type natriuretic peptide/guanylyl cyclase-B signaling prevents pulmonary arterial hypertension

Fig. 10: Therapeutic effects of CNP-53 in SuHx rodent models and its additive benefits with established therapies.

SuHx rat model. RVSP (a), RV/(LV + IVS) ratios (b) and BP (c) in SuHx rats treated with vehicle or CNP-53 (0.2 mg/kg/day) (n = 5 per group). d–g SuHx mouse model (wild-type). RVSP (d) and RV/(LV + IVS) ratios (e) in SuHx mice treated with vehicle, CNP-53 (0.2 mg/kg/day), macitentan (20 mg/kg/day) or the combination of macitentan and CNP-53. RVSP (f) and RV/(LV + IVS) ratios (g) in SuHx mice treated with vehicle, CNP-53, sotatercept (10 mg/kg twice weekly) or the combination of sotatercept and CNP-53 (controls and SuHx+vehicle groups, n = 5 each; macitentan group, n = 6; sotatercept group, n = 7). h–k SuHx mouse model (CNP ecKO). RVSP (h) and RV/(LV + IVS) ratios (i) in SuHx mice treated with vehicle, CNP-53 (0.2 mg/kg/day), macitentan (20 mg/kg/day) or the combination of macitentan and CNP-53. RVSP (j) and RV/(LV + IVS) ratios (k) in SuHx mice treated with vehicle, CNP-53, sotatercept (10 mg/kg twice weekly) or the combination of sotatercept and CNP-53 (controls and SuHx+vehicle groups, n = 5 each; macitentan group, n = 5; sotatercept group, n = 6). Data are presented as the mean ± SEM. P values were calculated using one-way ANOVA with Tukey’s multiple comparisons test.

Back to article page